. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Nat Rev Clin Oncol. 2013 Feb 5;10(4):211–224. doi: 10.1038/nrclinonc.2013.5

Table 4.

Pivotal clinical trials in the platinum-sensitive recurrent setting

Study	Agents	RR (%)	PFS (months)	HR	OS (months)	HR
ICON 4 (n = 802)¹⁰⁹	Carboplatin^*	54	9	0.76 P <0.001	24	0.82 P = 0.02
ICON 4 (n = 802)¹⁰⁹	Carboplatin + paclitaxel	66	12	0.76 P <0.001	29	0.82 P = 0.02
AGO (n = 366)¹¹⁰	Carboplatin	31	5.8	0.72 P = 0.003	17.3	0.96 P = 0.73
AGO (n = 366)¹¹⁰	Gemcitabin + carboplatin	47	8.6	0.72 P = 0.003	18	0.96 P = 0.73
CALYPSO (n = 976)¹¹¹	Carboplatin + paclitaxel	–	9.4	0.82 P = 0.005	31.5	0.99 P = 0.87
CALYPSO (n = 976)¹¹¹	Carboplatin + PLD	–	11.3	0.82 P = 0.005	31.5	0.99 P = 0.87
OCEANS (n = 484)¹¹²	Gemcitabine + carboplatin + placebo	57	8.4	0.48 P <0.0001	35.2	1.03 P = 0.84 Immature data
OCEANS (n = 484)¹¹²	Gemcitabine + carboplatin + bevacizumab	79	12.4	0.48 P <0.0001	33.3	1.03 P = 0.84 Immature data

Other non-taxane combinations were allowed.

Abbreviations: HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; RR, response rate.